Eduardo Leo‐Carnerero
A5005576610- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Anorectal Disease Treatments and Outcomes
- Adolescent and Pediatric Healthcare
- Pregnancy and Medication Impact
- Colorectal and Anal Carcinomas
- Liver Diseases and Immunity
- Salivary Gland Tumors Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Pharmaceutical studies and practices
- Biosimilars and Bioanalytical Methods
- Blood groups and transfusion
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Dermatology and Skin Diseases
- Healthcare Systems and Public Health
- Genetic and Kidney Cyst Diseases
- Helicobacter pylori-related gastroenterology studies
- Tuberculosis Research and Epidemiology
- Gastrointestinal motility and disorders
- Pancreatitis Pathology and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Acute Lymphoblastic Leukemia research
- Colorectal Cancer Surgical Treatments
Hospital Universitario Virgen del Rocío
2013-2025
Summary Background and Aims Data on the outcomes after switching from adalimumab (ADA) originator to ADA biosimilar are limited. The aim was compare treatment persistence, clinical efficacy, safety in inflammatory bowel disease patients who maintained vs. those switched biosimilar. Methods Patients receiving were remission at standard dose of included. formed non‐switch cohort (NSC), different biosimilars constituted switch (SC). Clinical defined as a Harvey–Bradshaw index ≤4 Crohn's partial...
Abstract Background For children born to mothers with inflammatory bowel disease (IBD), the effects of maternal inflammation and exposure biologic drugs during pregnancy may be significant. Elevated systemic markers are linked adverse birth outcomes impaired infant growth. However, specific evaluation within IBD context remains limited, impact drug on early anthropometric is still uncertain. Aim: analyze development malnutrition risk first year life based intrauterine breastfeeding biologics...
Abstract Background The therapeutic goal in inflammatory bowel disease (IBD), which includes Crohn´s (CD) and ulcerative colitis (UC), is the control of process frequently through biologic JAK-inhibitor therapies, are generally expensive may induce adverse effects. Unfortunately, only one-third patients respond to these treatments, there no markers that accurately predict this response. aim study was identify potential serum urinary metabolic biomarkers predictive IBD response different...
Venous thromboembolism (VTE), major adverse cardiovascular events (MACE), neoplasia, and serious infections are significant complications associated with Immune-mediated inflammatory diseases. Actually, the occurrence of such in these patients has been observed to be higher than that anticipated from classical risk factors alone. Additionally, administration anti-inflammatory treatments, as corticosteroids, diseases is recognized further elevate this risk. In Spain, data on prevalence...
ABSTRACT Background The EXIT trial found no difference in sustained remission at 12 months between inflammatory bowel disease (IBD) patients who withdrew anti‐TNF therapy [withdrawal arm (WA)] and those maintained treatment [maintenance (MA)]. Aims To compare the long‐term risk of relapse these groups assess response to resumption. Methods This was a follow‐up extension trial. We analysed outcomes clinical from start EXIT. Results included 125 (63 MA 62 WA). Median for 26 WA. cumulative...
The ideal length of treatment with thiopurines in patients ulcerative colitis (UC) sustained remission remains unknown. It is widely accepted that the drug withdrawal associated a worse outcome. aim this study was to analyze outcome after and identify predictors relapse.A multicenter retrospective designed. A total 102 UC who discontinued situation were included. All followed up until last revision or relapse (understood as occurrence signs symptoms required rescue treatment).After...
Summary Background The long‐term outcome of patients after antitumour necrosis factor alpha (anti‐TNF) discontinuation is not well known. Aims To assess the risk relapse in anti‐TNF discontinuation. Methods This was an extension evolution with inflammatory bowel disease (EVODIS) study (Crohn's or ulcerative colitis treated anti‐TNFs whom these drugs were withdrawn achieving clinical remission) based same cohort whose updated. Clinical remission defined as a Harvey–Bradshaw index ≤4 points...
Golimumab is a TNF-blocking agent indicated as second-line therapy in ulcerative colitis.To research the effectiveness and safety of golimumab patients with colitis clinical practice.Retrospective study colitis. All received 200 mg subcutaneously at week 0, 100 2. After induction treatment, each patient 50 sc. every 4 weeks body weight less than 80 kg, greater or equal to kg.Study group 23 patients, 7 whom were naive any anti-TNF therapy, 16 who had previously been treated an other...
The impact of biologics on the risk postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack evidence more relevant for ustekinumab and vedolizumab.To evaluate PC.A retrospective study was performed 37 centres. Patients treated with within 12 weeks before surgery were considered "exposed". exposure 30-day PC infections assessed by logistic regression propensity score-matched analysis.A total 1535 surgeries 1370 patients. Of them, 711...
Background: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders. Objective: To evaluate the effectiveness safety azathioprine as maintenance therapy inflammatory Design: This was a retrospective multicentre study. Methods: We included patients diagnosed with disorders treated monotherapy. Effectiveness evaluated at 1 year long term based on normalization stool frequency, absence pain, faecal urgency or fistula discharge (clinical remission), any...
Summary Background Ustekinumab is approved for ulcerative colitis (UC). Aims To assess the durability of ustekinumab in patients with UC and its short‐term effectiveness, tolerability clinical practice. Methods Retrospective, multicentre study who had received their first dose at least 16 weeks before inclusion. Patients were followed until treatment discontinuation or last visit. Only active disease start considered effectiveness analysis. stopped visit not to be subsequent remission....
(1) Background: Transition is a planned movement of paediatric patients to adult healthcare systems, and its implementation not yet established in all inflammatory bowel disease (IBD) units. The aim the study was evaluate impact transition on IBD outcomes. (2) Methods: Multicentre, retrospective observational transferred an unit between 2017-2020. Two groups were compared: (≥1 joint visit involving gastroenterologist, paediatrician, programme coordinator, parents patient) no-transition....
regenerative nodular hyperplasia (RNH) is a rare liver disease with an etiology that not well understood. Among the etiological factors are purine-analogue drugs such asazathioprine.we present case of 47-year-old patient diagnosed Crohn´s in treatment azathioprine due to corticosteroid dependency who developed RNH clinical and laboratory signs portal hypertension one year after starting treatment. After discontinuation azathioprine, started and, given poor progression, adalimumab. This was...
Abstract Background Understanding the impact of in utero exposure to biologic medications children is crucial providing recommendations during pregnancy. The effect biologics, particularly non-anti-TNF ones, on children's psychomotor development, has been inadequately studied. Our aim was evaluate biologics development first year life. Methods Data from born IBD patients included DUMBO registry with complete Age and Stages Questionnaire (AQS-3) available up 12 months age were analysed. a...
Abstract Background Primary aim: To assess the durability of ustekinumab treatment in patients with ulcerative colitis (UC). Secondary aims: short-term effectiveness, response, and tolerability clinical practice. Methods Retrospective, multicenter study including UC who had received 1st dose at least 16 weeks before inclusion. Patients were followed-up from to discontinuation or last visit. Only active disease [Partial Mayo Score (PMS)>2] start considered effectiveness analysis....
Abstract Background (1) To assess the risk of relapse at long-term after anti-TNF discontinuation, (2) to identify factors associated with relapse, (3) calculate response rate re-treatment same anti-TNF, (4) evaluate safety these drugs, and (5) investigate complications patients that relapsed. Methods A retrospective, observational, multicentre study conducted 39 Spanish centres. Crohn’s disease or ulcerative colitis who had been treated anti-TNFs in whom drugs withdrawn achieving clinical...